Urinary glycosaminoglycan composition in chronic glomerulonephritis

Journal of Nephrology

Volumn 18, Issue 2, 2005, Pages 154-160

  De Muro, Pierina ^a   Faedda, Rossana ^a,c   Satta, Andrea ^a   Finetti, Donatella ^a   Masala, Antonio ^a   Cigni, Alessandro ^a   Sanna, Giovanni Maria ^b   Cherchi, Gian Mario ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b Operative Unit   (Italy)

^c Ist Patol Spec Med   (Italy)

Author keywords

GAG protein complex; Glycosaminoglycans; Low sulfated chondroitin sulfate; Nephropathy; Proteoglycans; Slow migrating low sulfated chondroitin sulfate

Indexed keywords

2 DIETHYLAMINOETHANOL; ALCIAN BLUE; CELLULOSE ACETATE; CHONDROITIN SULFATE; CREATININE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEXURONIC ACID; PROTEOCHONDROITIN SULFATE;

ADULT; ARTICLE; CHEMICAL COMPOSITION; CLINICAL OBSERVATION; CONNECTIVE TISSUE; CONTROLLED STUDY; DENSITOMETRY; ELECTROPHORESIS; FEMALE; HUMAN; HUMAN TISSUE; ION EXCHANGE CHROMATOGRAPHY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NON INVASIVE MEASUREMENT; PROLIFERATIVE GLOMERULONEPHRITIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SULFATION; TISSUE METABOLISM; URINALYSIS; URINARY EXCRETION; URINE LEVEL;

ADULT; AGED; ALBUMINURIA; CASE-CONTROL STUDIES; CHRONIC DISEASE; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULONEPHRITIS, MEMBRANOUS; GLYCOSAMINOGLYCANS; HUMANS; MALE; MIDDLE AGED; PROTEOGLYCANS;

EID: 20744432341     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Davies M, Kastner S, Thomas GJ. Proteoglycans: their possible role in renal fibrosis. Kidney Int 1996; 54 (suppl): S55-60.
2. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 1705-8.
3. David G, Danneels A, Duerr J, Grootjans J, Mertens G, Nackaerts K, Romaris M, Schrurs B, Steinfeld R, Vekemans S. Heparan sulfate proteoglycans. Essential co-factors in receptor-mediated processes with relevance to the biology of the vascular wall. Atherosclerosis 1995; 118 (suppl): S57-67.
4. Kanwar YS, Farquhar MG. Anionic sites in the glomerular basement membrane. In vivo and in vitro localization to the laminae rarae by cationic probes. J Cell Biol 1979; 81: 137-53.
5. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 1980; 86: 688-93.
6. Rosenzweig LJ, Kanwar YS. Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest 1982; 47: 177-84.
7. Barnes JL, Radnik RA, Gilchrist EP, Venkatachalam MA. Size and charge selective permeability defects induced in glomerular basement membrane by a polycation. Kidney Int 1984; 25: 11-9.
8. Levin M, Gascoine P, Turner MW, Barratt TM. A highly cationic protein in plasma and urine of children with steroid-responsive nephrotic syndrome. Kidney Int 1989; 36: 867-77.
9. Vernier RL, Klein DJ, Sisson SP, Mahan JD, Oegema TR, Brown DM. Heparan sulfate-rich anionic sites in the human glomerular basement membrane. Decreased concentration in congenital nephrotic syndrome. N Engl J Med 1983; 309: 1001-9.
10. Vermylen C, Levin M, Mossman J, Barratt TM. Glomerular and urinary heparan sulphate in congenital nephrotic syndrome. Pediatr Nephrol 1989; 3: 122-9.
11. Baggio B, Gambaro G, Briani G, Favaro S, Borsatti A. Urinary excretion of glycosaminoglycans and brush border and lysosomal enzymes as markers of glomerular and tubular involvement in kidney diseases. Contrib Nephrol 1984; 42: 107-10.
12. Baggio B, Briani G, Cicerello E, Gambaro G, Giorato C, Iori E, Lavagnini T, Crepaldi G. Effects of imidazole-2-hydroxibenzoate on glycosaminoglycan and albumin urinary excretion in type 1 diabetic patients. Nephron 1988; 50: 45-9.
13. Tencer J, Torffvit O, Bjornsson S, Thysell H, Grubb A, Rippe B. Decreased excretion of glycosaminoglycans in patients with primary glomerular diseases. Clin Nephrol 1997; 48: 212-9.
14. De Muro P, Faedda R, Formato M, Re F, Satta A, Cherchi GM, Carcassi A. Urinary glycosaminoglycans in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2001; 19: 125-30.
15. Staprans I, Garon SJ, Hopper J, Felts JM. Characterization of glycosaminoglycans in urine from patients with nephrotic syndrome and control subjects, and their effects on lipoprotein lipase. Biochim Biophys Acta 1981; 678: 414-22.
16. Bitter T, Muir HM. Modified uronic acid carbazole reaction. Anal Biochem 1962; 4: 330-4.
17. Cappelletti R, Del Rosso M, Chiarugi VP. A new electrophoretic method for the complete separation of all non-animal glycosaminoglycans in a monodimensional run. Anal Biochem 1979; 99: 311-5.
18. Cherchi GM, Formato M, Demuro, P, Masserini M, Varani I, DeLuca G. Modifications of low density lipoprotein induced by the interaction with human plasma glycosaminoglycan-protein complexes. Biochim Biophys Acta 1994; 1212: 345-52.
19. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
20. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003; 63: 809-25.
21. Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57: 385-400.
22. Mitsuhashi H, Tsukada Y, Ono K, Yano S, Naruse T. Urine glycosaminoglycans and heparan sulfate excretions in adult patients with glomerular diseases. Clin Nephrol 1993; 39: 231-8.
23. Imanari T, Shinbo A, Ochiai H, Ikei T, Koshiishi I, Toyoda H. Study on proteoglycans having low-sulfate chondroitin 4-sulfate in human urine and serum. J Pharmacobiodyn 1992; 15: 231-7.
24. Balduyck M, Albani D, Jourdain M, Mizon C, Tournoys A, Drobecq H, Fourrier F, Mizon J. Inflammation-induced systemic proteolysis of inter-alpha-inhibitor in plasma from patients with sepsis. J Lab Clin Med 2000; 135: 188-98.
25. Mizon C, Queyrel V, Balduyck M, Drobecq H, Hachulla E, Mizon J. Human pre-alpha-inhibitor is a positive acute-phase protein that is more susceptible than inter-alpha-inhibitor to proteolysis by stimulated neutrophils. Eur J Clin Invest 2000; 30: 79-86.
26. Kuwajima S, Noda T, Izumi Y, Kitao H, Naka K, Okuda K. Urinary trypsin inhibitor as an acute phase reactant. Rinsho Byori 1992; 40: 751-5.
27. Bower L, Warren C, Manley G. Human serum and urine glycosaminoglycans in health and in patients with chronic renal failure. Ann Clin Biochem 1992; 29: 190-5.
28. Warren C, Manley G. Measurement of heparan sulphate in normal human serum by laser nephelometry. Clin Chim Acta 1984; 137: 355-9.
29. Wasteson A, Wessler E. Molecular size and xylose content of urinary glycosaminoglycans. Biochim Biophys Acta 1971; 252: 13-7.
30. Hadad SJ, Michelacci YM, Schor N. Proteoglycans and glycosaminoglycans synthesized in vitro by mesangial cells from normal and diabetic rats. Biochim Biophys Acta 1996; 1290: 18-28.
31. Border WA, Okuda S, Languino LR, Ruoslahti E. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int 1990; 37: 689-95.
32. Smoyer WE, Mundel P. Regulation of podocyte structure during the development of nephrotic syndrome. J Mol Med 1998; 76: 172-83.